CAR+ extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR T cells

被引：2

作者：

Storci, Gianluca ^{[1
]}

De Felice, Francesco ^{[1
,2
]}

Ricci, Francesca ^{[1
]}

Santi, Spartaco ^{[3
,4
]}

Messelodi, Daria ^{[1
]}

Bertuccio, Salvatore Nicola ^{[1
]}

Laprovitera, Noemi ^{[1
]}

Dicataldo, Michele ^{[1
,2
]}

Rossini, Lucrezia ^{[2
]}

De Matteis, Serena ^{[1
]}

Casadei, Beatrice ^{[1
]}

Vaglio, Francesca ^{[1
]}

Ursi, Margherita ^{[1
,2
]}

Barbato, Francesco ^{[1
,2
]}

Roberto, Marcello ^{[1
,2
]}

Guarino, Maria ^{[1
]}

Asioli, Gian Maria ^{[1
]}

Arpinati, Mario ^{[1
]}

Cortelli, Pietro ^{[5
,6
]}

Maffini, Enrico ^{[1
]}

Tomassini, Enrica ^{[1
]}

Tassoni, Marta ^{[2
]}

Cavallo, Carola ^{[7
]}

Iannotta, Francesco ^{[1
]}

Naddeo, Maria ^{[1
,2
]}

Tazzari, Pier Luigi ^{[1
]}

Dan, Elisa ^{[1
]}

Pellegrini, Cinzia ^{[1
]}

Guadagnuolo, Serafina ^{[1
]}

Carella, Matteo ^{[1
,2
]}

Sinigaglia, Barbara ^{[1
]}

Pirazzini, Chiara ^{[2
]}

Severi, Caterina ^{[8
]}

Garagnani, Paolo ^{[1
,2
]}

Kwiatkowska, Katarzyna Malgorzata ^{[2
]}

Ferracin, Manuela ^{[1
,2
]}

Zinzani, Pier Luigi ^{[2
,9
]}

Bonafe, Massimiliano ^{[1
,2
]}

Bonifazi, Francesca ^{[1
]}

机构：

[1] IRCCS, Azienda Osped Univ Bologna, Bologna, Italy

[2] Univ Bologna, Dipartimento Sci Med & Chirurg, Bologna, Italy

[3] IRCCS, Ist Ortoped Rizzoli, Bologna, Italy

[4] Natl Res Council Italy, Inst Mol Genet, Bologna, Italy

[5] Univ Bologna, Bellaria Hosp, Dept Biomed & Neuromotor Sci, Bologna, Italy

[6] IRCCS, Bellaria Hosp, Inst Neurol Sci Bologna, Bologna, Italy

[7] IRCCS, Res & Innovat Technol Dept, Ist Ortoped Rizzoli, Lab Ramses, Bologna, Italy

[8] Abbelight, Cachan, France

[9] IRCCS, Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy

来源：

JOURNAL OF CLINICAL INVESTIGATION | 2024年 / 134卷 / 14期

关键词：

THERAPY; NEUROTOXICITY; MANAGEMENT; CHILDREN; ADULTS; BLOOD;

D O I：

10.1172/JCI173096

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

BACKGROUND. Predicting immune effector cell-associated neurotoxicity syndrome (ICANS) in patients infused with CAR T cells is still a conundrum. This complication, thought to be consequent to CAR T cell activation, arises a few days after infusion, when circulating CAR T cells are scarce and specific CAR T cell-derived biomarkers are lacking. METHODS. CAR + extracellular vesicle (CAR + EV) release was assessed in human CD19.CAR T cells cocultured with CD19 + target cells. A prospective cohort of 100 patients with B cell lymphoma infused with approved CD19.CAR T cell products was assessed for plasma CAR + EVs as biomarkers of in vivo CD19.CAR T cell activation. Human induced pluripotent stem cell- derived (iPSC-derived) neural cells were used as a model for CAR + EV-induced neurotoxicity. RESULTS. In vitro release of CAR + EVs occurs within 1 hour after target engagement. Plasma CAR + EVs are detectable 1 hour after infusion. A concentration greater than 132.8 CAR + EVs/ mu L at hour +1 or greater than 224.5 CAR + EVs/ mu L at day +1 predicted ICANS in advance of 4 days, with a sensitivity and a specificity outperforming other ICANS predictors. ENO2 + nanoparticles were released by iPSC-derived neural cells upon CAR + EV exposure and were increased in plasma of patients with ICANS. CONCLUSION. Plasma CAR + EVs are an immediate signal of CD19.CAR T cell activation, are suitable predictors of neurotoxicity, and may be involved in ICANS pathogenesis.

引用

页数：17

共 50 条

[41] Real-World Treatment Patterns After CD19-Directed CAR T Cell Therapy Among Patients with Diffuse Large B Cell Lymphoma
Jessica J. Jalbert
Ning Wu
Chieh-I Chen
Srikanth Ambati
Wenzhen Ge
Jon E. Arnason
Advances in Therapy, 2022, 39 : 2630 - 2640
[42] In-Field Failures in Patients Undergoing Bridging Radiotherapy for CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Recurrent/Refractory Large B-Cell Lymphomas
Sim, A. J.
Figura, N. B.
Dohm, A. E.
Chavez, J. C.
Shah, B. D.
Khimani, F.
Lazaryan, A.
Davila, M. L.
Bachmeier, C.
Nishihori, T.
Liu, H. D.
Kim, S.
Locke, F. L.
Jain, M. D.
Robinson, T. J.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : S131 - S131
[43] Polatuzumab-bendamustine-rituximab as bridge to CD19-directed CAR T cells in mantle cell lymphoma refractory to ibrutinib and venetoclax
Perriello, Vincenzo Maria
Falini, Lorenza
Ruggeri, Loredana
Sorcini, Daniele
Ballanti, Stelvio
Flenghi, Leonardo
Baffa, Nicodemo
Covarelli, Piero
Sportoletti, Paolo
Pierini, Antonio
Falini, Brunangelo
EJHAEM, 2023, 4 (02): : 559 - 562
[44] Predictive short/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed/refractory B-cell lymphomas
Xu, Hao
Li, Ningwen
Wang, Gaoxiang
Cao, Yang
FRONTIERS IN IMMUNOLOGY, 2023, 14
[45] Tumor gene expression signatures associated with outcome in large B-cell lymphoma treated with CD19-directed CAR T-cell therapy (axicabtagene ciloleucel)
Tian, Yuan
Budka, Justin
Locke, Frederick L.
Westin, Jason R.
To, Christina
Tiwari, Gayatri
Mao, Daqin
Bedognetti, Davide
Shen, Rhine R.
Andrade, Jorge
Filosto, Simone
FRONTIERS IN ONCOLOGY, 2025, 15
[46] Hypofibrinogenemia in Patients Receiving CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Large B Cell Lymphoma: A Single Institution Experience
Hashmi, Hamza
Mirza, Abu-Sayeef
Darwin, Alicia
Logothetis, Constantine
Garcia, Franco
Kommalapati, Anuhya
Bachmeier, Christina A.
Benson, Kaaron
Chavez, Julio C.
Shah, Bijal D.
Pinilla-Ibarz, Javier
Khimani, Farhad
Lazaryan, Aleksandr
Liu, Hien
Davila, Marco L.
Nishihori, Taiga
Jain, Michael D.
Locke, Frederick L.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S257 - S258
[47] Tumor gene signature associated with neurotoxicity in R/R B-ALL patients treated with JCAR015, a CD19-directed CAR T cell product.
Olson, N. Eric
Ragan, Seamus P.
Ponko, Stefan
Trede, Nikolaus S.
Stern, Howard Marvin
Sutherland, Claire L.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[48] Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials
Westin, Jason R.
Kersten, Marie Jose
Salles, Gilles
Abramson, Jeremy S.
Schuster, Stephen J.
Locke, Frederick L.
Andreadis, Charalambos
AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (10) : 1295 - 1312
[49] Clinical Response in Relapsed/Refractory (R/R) B-NHL Treated with the CD19-Directed CAR T-Cell Product JWCAR029
Ying, Zhitao
Xu, Pengpeng
Wang, Li
Cheng, Shu
Wu, Wen
Wang, Wen
Hao, Ming
Yang, Su
Lam, Harry
Li, James
Zheng, Hongxia
Zhao, Weili
Song, Yuqin
Zhu, Jun
BLOOD, 2019, 134
[50] Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma
Mirza, Abu-Sayeef
Kumar, Ambuj
Hashmi, Hamza
Garcia, Franco
Logothetis, Constantine N.
Darwin, Alicia
Faramand, Rawan
Reid, Kayla
Bachmeier, Christina
Chavez, Julio C.
Shah, Bijal
Pinilla-Ibarz, Javier
Khimani, Farhad
Lazaryan, Aleksandr
Liu, Hien
Davila, Marco L.
Nishihori, Taiga
Locke, Frederick L.
Jain, Michael D.
TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (03): : 242.e1 - 242.e6

← 1 2 3 4 5 →